Ghoti Ichthus
Genesis 18:32, 2 Chronicles 7:14, Acts 5:29
Drugs.com and DrugBank.ca links below article
Feb 16, 2025
"Introducing the first new class of pain medicine approved by the U.S. Food and Drug Administration in more than two decades.
The FDA has approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive like opioids, which have been the standard of care in pain-killers for 20 years.
Boston-based Vertex Pharmaceuticals is set to sell the twice daily pills for $15 per dose under the name Journavx.
The analgesic works by “targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system—before pain signals reach the brain.”
“Today’s approval is an important public health milestone in acute pain management,” said FDA spokesperson Jacqueline Corrigan-Curay, J.D., M.D. “It provides patients with another treatment option.”
The efficacy of Journavx (aka suzetrigine) was evaluated in two randomized, double-blind, placebo- and active-controlled trials of acute surgical pain, both of which demonstrated a statistically-significant superior reduction in pain, compared to placebo."
More
www.goodnewsnetwork.org
Here's the Drugs.com link to Journavx with patient and professional info
www.drugs.com
Here's the DrugBank.ca link to Journavx
FDA Approves Opioid-free Pain Medication That Finally Delivers Relief Without Addiction
By Good News NetworkFeb 16, 2025
"Introducing the first new class of pain medicine approved by the U.S. Food and Drug Administration in more than two decades.
The FDA has approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive like opioids, which have been the standard of care in pain-killers for 20 years.
Boston-based Vertex Pharmaceuticals is set to sell the twice daily pills for $15 per dose under the name Journavx.
The analgesic works by “targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system—before pain signals reach the brain.”
“Today’s approval is an important public health milestone in acute pain management,” said FDA spokesperson Jacqueline Corrigan-Curay, J.D., M.D. “It provides patients with another treatment option.”
The efficacy of Journavx (aka suzetrigine) was evaluated in two randomized, double-blind, placebo- and active-controlled trials of acute surgical pain, both of which demonstrated a statistically-significant superior reduction in pain, compared to placebo."
More
FDA Approves Opioid-free Pain Medication That Finally Delivers Relief Without Addiction
The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive like opioids.
www.goodnewsnetwork.org
Here's the Drugs.com link to Journavx with patient and professional info
Journavx: Uses, Dosage, Side Effects, Warnings - Drugs.com
Journavx (suzetrigine) is a new non-opioid pain-relieving tablet used to treat short-term moderate to severe pain. includes Journavx side effects, uses, interactions, and more.
www.drugs.com
Here's the DrugBank.ca link to Journavx
